Subscribe

The Missing Elements in Our Value-Based Care Discussions

VBCC - August 2015, Vol 6, No 7 - VBCC Perspectives
Kevin Cast

Although we all admire and support the efforts put forth by many experts to help quantify the “real” value of cancer medications, they still miss the mark in 2 dramatic ways:

1. Is it really reasonable to expect a person with newly diagnosed disease (and his or her spouse or caregiver) to understand the complexities of a net health benefit score,1 or of the DrugAbacus?2

I recently went through this experience with my father-in-law as he was diagnosed (and recently passed away) with mesothelioma. No number could have made the decision to undergo chemotherapy any simpler.

2. We all understand and even acknowledge that the cost of medication is only a portion of the total cost to treat cancer, yet none of the recently discussed/developed tools factor the cost of hospitalizations, healthcare providers, laboratory tests, magnetic resonance imaging, and so on, into the equation. We continue to focus on a small portion of the total cost of treatment, rather than the entire picture.

As pharmaceutical companies develop more targeted and efficacious medications, we will expect the price of the drugs to escalate, but this can only be affordable if the other associated costs, in turn, diminish. The US healthcare system needs to work together and become aligned regarding the cost of care.




References

  1. Schnipper LE, Davidson NE, Wollins DS, et al. American Society of Clinical Oncology statement: a conceptual framework to assess the value of cancer treatment options. J Clin Oncol. 2015 Jun 22. Epub ahead of print.
  2. Loftus P. How much should cancer drugs cost? Memorial Sloan Kettering doctors create pricing calculator that weighs factors such as side effects, extra years of life. Wall Street Journal. June 18, 2015.
Related Items
The NCCN Evidence Blocks and Clinical Practice Guidelines: Identifying Truth
Robert W. Carlson, MD, Al B. Benson III, MD, FACP
VBCC - March 2016, Vol 7, No 2 published on March 21, 2016 in Online First, VBCC Perspectives
The NCCN New Tool to Assess Value Discourages Patients’ Hope
Robert Goldberg, PhD
VBCC - November 2015, Vol 6, No 10 published on November 12, 2015 in VBCC Perspectives
AstraZeneca Commentary on Oncology Value Tools
Diane Sullivan
VBCC - October 2015, Vol 6, No 9 published on October 17, 2015 in VBCC Perspectives
The Role of Oncologists in Defining the Value of Cancer Therapy
Michael Kolodziej, MD
VBCC - August 2015, Vol 6, No 7 published on August 18, 2015 in VBCC Perspectives
ASCO’s Value Framework a Powerful Tool for Shared Decision-Making
Neil B. Minkoff, MD
VBCC - August 2015, Vol 6, No 7 published on August 18, 2015 in VBCC Perspectives
Emerging Tools for Assessing Value: Pros and Cons
Kirby J. Eng, RPh
VBCC - August 2015, Vol 6, No 7 published on August 18, 2015 in VBCC Perspectives
ASCO’s Value Framework Promoting Accountability and Transparency
Joseph Morse
VBCC - August 2015, Vol 6, No 7 published on August 18, 2015 in VBCC Perspectives
ASCO’s Net Health Benefit: A Palliative Care Regimen Scores Higher than Active Treatment
Pamela Pelizzari, MPH, Bruce Pyenson, FSA, MAAA
VBCC - August 2015, Vol 6, No 7 published on August 18, 2015 in VBCC Perspectives
Addressing the Value of New Cancer Treatment Options Using the ASCO Model
Philip E. Johnson, MS, RPh, FASHP
VBCC - August 2015, Vol 6, No 7 published on August 18, 2015 in VBCC Perspectives
ASCO’s Value Framework Abandons the Hippocratic Oath
Robert Goldberg, PhD
VBCC - July 2015, Vol 6, No 6 published on July 21, 2015 in VBCC Perspectives
Last modified: August 18, 2015
  • Rheumatology Practice Management
  • Lynx CME
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology